CD8A and malaria: All vaccinated volunteers became infected with malaria during CHMI with a median time to diagnosis of 13 days compared to 13.25 days in controls.<h4>Conclusions</h4>Though this study further indicates ChAd/MVA as a safe, highly effective platform for driving CD8 <sup>+</sup> responses specific to liver-stage malaria antigens, the promise of LSA1 and LSAP2 as potential candidates shown preclinically has not translated to protection from infection in humans.Clinical Trial Registration ClinicalTrials.gov (Ref: NCT03203421), date of registration, 3 <sup>rd</sup> July 2017.